HK Stock Market Move | LYGEND RESOURCE (02245) rose over 7% again, and the A-share main board IPO has been successfully passed. The net profit for the first half of the year is expected to increase by 50% to 70%.
Liqin Resources (02245) rose by over 7% again, as of press time, it rose by 4.76% to HK$14.08, with a turnover of HK$18.3255 million.
LYGEND RESOURCE (02245) rose more than 7% again, as of the press release, rising 4.76% to HK$14.08, with a trading volume of HK$183.255 million.
On the news front, LYGEND RESOURCE has successfully passed the review of the Shenzhen Stock Exchange's main board listing committee, becoming the benchmark enterprise for the "H to A" nickel industry since the full implementation of the registration system. The company plans to raise 4.047 billion yuan, all of which will be invested in two major industrial projects: the wet-process slag resource utilization demonstration project and the MHP refining production project, to continuously expand the nickel deep processing and recycling capacity.
It is worth noting that LYGEND RESOURCE's IPO application materials include voluntary profit forecasts for the year 2026. The company expects annual operating income of 56.413 billion yuan, a year-on-year increase of 40.14%; expected net profit of 6.001 billion yuan, a year-on-year increase of 26.35%. In addition, the company recently announced a profit increase for the first half of the year, expecting a profit of 2.25 billion to 2.5 billion yuan in the first half of the year, a year-on-year increase of approximately 57.3% to 74.8%.
Related Articles

TSAKER NE(01986) announces a half-year profit of no less than 90 million yuan for shareholders, with a year-on-year growth rate of no less than 867.7%.

KEYMED BIO-B (02162): CM512 has been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center.

A-share market midday review: Multiple factors affecting the market! The index fell on shrinking volume, the Science and Technology Innovation 50 Index dropped more than 4%, and semiconductor stocks fell across the board.
TSAKER NE(01986) announces a half-year profit of no less than 90 million yuan for shareholders, with a year-on-year growth rate of no less than 867.7%.

KEYMED BIO-B (02162): CM512 has been included in the list of breakthrough therapies by the National Medical Products Administration Drug Evaluation Center.

A-share market midday review: Multiple factors affecting the market! The index fell on shrinking volume, the Science and Technology Innovation 50 Index dropped more than 4%, and semiconductor stocks fell across the board.

RECOMMEND





